Company Directory - MassBio
Company Details - MassBio
MassBio
WebsiteUnited States
MassBio is a non-profit organization that provides a robust network for the life sciences sector in Massachusetts, supporting biotechnology companies and fostering innovation.
CCI Score
CCI Score: MassBio
57.77
-0.03%
Latest Event
MassBio Reacts to Biosecure Act Passage
MassBio CEO Kendalle Burlin O'Connell criticized the Biosecure Act passed by the U.S. House for potentially harming domestic biomanufacturing and innovation. In a statement, MassBio emphasized the need to modify the legislation to provide adequate time and financial resources for valid transition, balancing national security concerns with the vitality of the biopharmaceutical ecosystem.
Take Action
So what can you do? Support MassBio by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
LEADER
MassBio is currently rated as a Leader.
Latest Events
- SEP102024
MassBio CEO Kendalle Burlin O'Connell criticized the Biosecure Act passed by the U.S. House for potentially harming domestic biomanufacturing and innovation. In a statement, MassBio emphasized the need to modify the legislation to provide adequate time and financial resources for valid transition, balancing national security concerns with the vitality of the biopharmaceutical ecosystem.
+40
Executive Political Engagement
March 28
MassBio's CEO engaged directly with the legislative process by urging the Senate to amend the Biosecure Act. This executive political engagement reflects a commitment to ensuring that policies addressing national security do not inadvertently damage domestic innovation and worker interests in the biopharmaceutical sector.
Biosecure bill that worries Mass. biotech leaders passes U.S. House
- AUG272024
MassBio released its annual 'Industry Snapshot' report on August 27, 2024, showing that despite industry layoffs and funding challenges, Massachusetts' biopharma sector achieved a net gain of 3,000 jobs, largely driven by growth in research and development. The report indicates strong regional economic benefits and a broad distribution of venture capital investments across the state.
+70
Business Practices and Ethical Responsibility
March 28
MassBio’s report demonstrates a proactive role in fostering a vibrant life sciences community that creates substantial new job opportunities. This contributes to ethical business practices by supporting innovation and worker opportunities in a critical sector.
Mass. life sciences sector adds 3,000 new jobs, despite industry layoffs
+70
Technology and Services Impact
March 28
The report highlights robust growth in research and development within the biopharma sector, signaling strong technological advancement and contribution to scientific innovation. This reinforces the positive impact of technology and services on societal well‐being.
Mass. life sciences sector adds 3,000 new jobs, despite industry layoffs
+80
Economic and Structural Influence
March 28
The net addition of 3,000 jobs significantly bolsters local economic structures and community resilience. This growth helps to counteract previous layoffs and supports broader economic development, aligning with positive structural influence on society.
Mass. life sciences sector adds 3,000 new jobs, despite industry layoffs
- DEC122023
MassBio’s Director of Diversity, Equity, and Inclusion has reflected on the release and media coverage of the 2023 DEI report. The report outlines current challenges in representation, resource limitations for DEI officers, and low participation rates in supplier diversity initiatives among member companies—all while reaffirming a commitment to advancing meaningful diversity and inclusion practices in the life sciences sector.
+70
Labor Relations and Human Rights Practices
March 28
MassBio's publication and reflection on its 2023 DEI report underscores a proactive, progressive effort focused on enhancing diversity, equity, and inclusion within the life sciences industry. The report not only highlights current gaps—such as limited support for DEI officers and low supplier diversity program adoption—but also signals an ongoing commitment to addressing these issues. Such initiatives align with anti-authoritarian, supportive practices that emphasize fairness, transparency, and sustainable worker rights.
- NOV012023
MassBio released its 2023 Diversity, Equity, & Inclusion Report, which highlights improved gender diversity in leadership roles and the adoption of DEI best practices, including the CEO Pledge, while also noting the persistent underrepresentation of communities of color.
+70
Executive Political Engagement
March 28
The report features the CEO Pledge that signals proactive executive engagement in promoting diversity and accountability. Such actions counter authoritarian and exclusionary practices by involving top leadership in advancing inclusive policies.
+80
Labor Relations and Human Rights Practices
March 28
The DEI report documents measurable improvements in gender representation and outlines initiatives for recruiting and advancing diverse talent, which supports worker rights and fights systemic inequities that can fuel authoritarian practices.
- SEP012023
MassBio, a non-profit organization supporting the life sciences sector in Massachusetts, is actively engaging with lawmakers and regulators to shape a legislative and regulatory environment that fosters innovation and supports patient access. The advocacy efforts include building enduring partnerships with policymakers such as Members of Congress, while also critiquing policies like the Inflation Reduction Act and the 340B program for their potential to disrupt industry innovation and patient access.
+70
Executive Political Engagement
March 28
MassBio's proactive engagement with policymakers, including its direct collaboration with members of Congress, demonstrates a strong commitment to shaping progressive regulatory and legislative frameworks. Their advocacy for sensible immigration policies, increased NIH funding, and a balanced reimbursement landscape supports innovation and patient access. This public political engagement aligns with anti-authoritarian and progressive values by striving for transparency, accountability, and policy reforms that protect public interests.
- JAN012023
MassBio announced a multifaceted policy agenda aimed at reauthorizing the Life Sciences Initiative, promoting educational equity through coalition efforts, and advocating for fair drug pricing reforms under the Inflation Reduction Act during the upcoming 2023 legislative sessions at both state and federal levels.
+70
Political Contributions and Lobbying Efforts
March 28
MassBio is actively engaging in lobbying and public advocacy by educating legislative leaders on critical issues affecting the life sciences sector such as reauthorization of the Life Sciences Initiative, increased educational investment, and drug pricing transparency. This engagement supports democratic accountability and aligns with progressive, anti-fascist values by promoting inclusive policy-making.
Looking Ahead to the 2023 Legislative Sessions in Massachusetts and in Congress
Alternatives
Melbourne, Australia
65.05
Corporation
0.00
Washington, United States
69.42
Washington, D.C., United States
63.80
Mountain View, United States
-8.68
Geneva, Switzerland
54.72
Medford, USA
0.00
Corporation
67.98
Corporation
47.87
Corporation
38.15
Industries
- 541611
- Administrative Management and General Management Consulting Services
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 541720
- Research and Development in the Social Sciences and Humanities
- 611310
- Colleges, Universities, and Professional Schools